Sales & Marketing News | pharmaphorum

News

FDA clears first drug for Niemann-Pick disease

Zevra Therapeutics' Miplyffa has become the first medicine to be approved by the FDA for the ultra-rare genetic disorder Niemann-Pick disease.

News

J&J tries to push talc bankruptcy over the line once again

Johnson & Johnson's long-running effort to put litigation claiming its talc products caused cancer has continued with a third attempt to place a subsidiary company into bankruptcy.

News

chessboard with two knights facing each other

FTC sues PBMs over 'perverse' rebate system

The Federal Trade Commission (FTC) has sued the top three pharmacy benefit managers (PBMs) in the US for operating a "perverse drug rebate system" that it claims artificially inflated the p

News

J&J nets another key approval for blockbuster hope Rybrevant

Johnson & Johnson's target of $5 billion in sales for its EGFRxMET bispecific antibody Rybrevant has moved a step closer, after a new FDA approval in non-small cell lung cancer (NSCLC).

News

Vanda slams FDA rejection of gastroparesis drug

The FDA has declined to approve Vanda Pharma's tradipitant for delayed gastric emptying (gastroparesis), prompting a furious response from the company.

News

ICER mulls GSK COPD drugs ahead of next Medicare negotiation

The list for the next round of medicines that will be subject to Medicare price negotiations isn’t in yet, but the Institute for Clinical and Economic Review (ICER) reckons a chronic obstru

FDA clears first drug for Niemann-Pick disease

J&J tries to push talc bankruptcy over the line once again

FTC sues PBMs over 'perverse' rebate system

J&J nets another key approval for blockbuster hope Rybrevant

Vanda slams FDA rejection of gastroparesis drug

ICER mulls GSK COPD drugs ahead of next Medicare negotiation

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

News

Editor's Picks